Cincinnati, OHNCT00903110Now EnrollingIRB Ready

IGF1 Deficiency Clinical Trial in Cincinnati, OH

Access cutting-edge igf1 deficiency treatment through this clinical trial at a research site in Cincinnati. Study-provided care at no cost to qualified participants.

Sponsored by Esteve Pharmaceuticals, S.A.

Quick Self-Assessment

See if you qualify for this Cincinnati location

Preparing your pre-screening questions…

Expert Care in Cincinnati

Access igf1 deficiency specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related igf1 deficiency treatment provided free

Apply for This Cincinnati Location

Check if you qualify for this igf1 deficiency clinical trial in Cincinnati, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cincinnati

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cincinnati site if eligible
  4. 4Begin participation

About This IGF1 Deficiency Study in Cincinnati

The Increlex® Global Registry is a descriptive, multicenter, observational, prospective, open-ended, non interventional, post-authorisation surveillance registry. The main purpose of this global registry is to collect, analyse and report safety data during and up to at least 5 years after the end of treatment in children and adolescents receiving Increlex® therapy for SPIGFD according to the locally approved product information.

Sponsor: Esteve Pharmaceuticals, S.A.

Who Can Participate

Inclusion Criteria

For US : patients starting or planning to start or currently receiving treatment with Increlex® therapy for severe primary IGF-1 deficiency as defined by the US Increlex® prescribing information or for growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.For EU : patients starting or planning to start or currently receiving treatment with Increlex® therapy according to the locally approved product information.
Parents or legally authorized representatives if applicable must give signed informed consent before any registry-related activities are conducted. Assent from the subject should also be obtained as appropriate

Exclusion Criteria

Subject currently participating in an Increlex® clinical trial
Subject currently participating in any clinical trial for growth retardation
Patient with any contraindication to Increlex® or any condition subject to special warning as per the locally approved label
For US patients, these include patients with hypersensitivity to the active substance or any of the excipients, patients with active or suspected neoplasia and patients with closed epiphyses.
For EU patients: these include patients with hypersensitivity to the active substance or any of the excipients, patients with active or suspected neoplasia or any condition or medical history which increases the risk of benign or malignant neoplasia and patients with closed epiphyses

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cincinnati?

Yes, this clinical trial (NCT00903110) has an active research site in Cincinnati, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

IGF1 Deficiency Treatment Options in Cincinnati, OH

If you're searching for igf1 deficiency treatment options in Cincinnati, OH, this clinical trial (NCT00903110) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cincinnati research site is actively enrolling participants for this clinical trial. You'll receive care from experienced igf1 deficiency specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all igf1 deficiency clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Cincinnati, OH

See all interstitial cystitis clinical trials recruiting in Cincinnati — not just this study.

Browse Interstitial Cystitis Trials in Cincinnati →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Cincinnati?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cincinnati, OH